Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-997-2400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.09 million
Profitability
Miscellaneous
Employees152
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
What is Adamis Pharmaceuticals' stock symbol?
Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
How were Adamis Pharmaceuticals' earnings last quarter?
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) released its earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.03. The specialty pharmaceutical company had revenue of $5.77 million for the quarter, compared to analysts' expectations of $5.82 million. Adamis Pharmaceuticals had a negative net margin of 205.32% and a negative return on equity of 86.04%. View Adamis Pharmaceuticals' Earnings History.
When is Adamis Pharmaceuticals' next earnings date?
What price target have analysts set for ADMP?
5 brokerages have issued twelve-month target prices for Adamis Pharmaceuticals' stock. Their forecasts range from $1.10 to $7.00. On average, they expect Adamis Pharmaceuticals' share price to reach $4.53 in the next year. This suggests a possible upside of 728.5% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.
What is the consensus analysts' recommendation for Adamis Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals.
Has Adamis Pharmaceuticals been receiving favorable news coverage?
News coverage about ADMP stock has been trending neutral this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Adamis Pharmaceuticals.
Who are some of Adamis Pharmaceuticals' key competitors?
Some companies that are related to Adamis Pharmaceuticals include Harrow Health (HROW), Avadel Pharmaceuticals (AVDL), American Brivision (Holding) (ABVC), Axovant Gene Therapies (AXGT), Generex Biotechnology (GNBT), MEI Pharma (MEIP), Mustang Bio (MBIO), CytoDyn (CYDY), Menlo Therapeutics (MNLO), Sesen Bio (SESN), OASMIA PHARMACE/ADR (OASM), PhaseBio Pharmaceuticals (PHAS), Kala Pharmaceuticals (KALA), Scpharmaceuticals (SCPH) and Adamas Pharmaceuticals (ADMS).
What other stocks do shareholders of Adamis Pharmaceuticals own?
Who are Adamis Pharmaceuticals' key executives?
Adamis Pharmaceuticals' management team includes the folowing people:
- Mr. Richard C. Williams, Chairman & Consultant (Age 75)
- Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)
- Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)
- Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)
- Mr. Robert B. Rothermel, Consultant & Director (Age 75)
Who are Adamis Pharmaceuticals' major shareholders?
Adamis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.14%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals.
Which institutional investors are buying Adamis Pharmaceuticals stock?
How do I buy shares of Adamis Pharmaceuticals?
Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Adamis Pharmaceuticals' stock price today?
One share of ADMP stock can currently be purchased for approximately $0.55.
How big of a company is Adamis Pharmaceuticals?
Adamis Pharmaceuticals has a market capitalization of $33.56 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.
What is Adamis Pharmaceuticals' official website?
How can I contact Adamis Pharmaceuticals?
Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]
MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
